Search results
Showing 151 to 165 of 301 results for breast cancer
In development [GID-TA11546] Expected publication date: 10 September 2025
A review of the impact our evidence-based guidance has on improvements in lung cancer.
Awaiting development [GID-TA11519] Expected publication date: TBC
Awaiting development [GID-TA11231] Expected publication date: TBC
Evidence-based recommendations on nivolumab (Opdivo) with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer in adults.
Our health inequalities guidance supports strategies that improve population health as a whole, while offering particular benefit to the most disadvantaged
Studies show that risk-reducing surgery significantly reduces risk of breast cancer, but there is insufficient evidence to decide...
of mutations and need adjustment for pathological subtypes of breast and ovarian cancer, which are particularly associated...
Breast cancer (locally advanced or metastatic) - ixabepilone [ID377]
Discontinued [GID-TAG403]
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer (TA951)
Evidence-based recommendations on olaparib (Lynparza) with abiraterone for untreated hormone-relapsed metastatic prostate cancer in adults.
This quality standard covers the recognition and initial management of ovarian cancer. It describes high-quality care in priority areas for improvement.
Etirinotecan pegol for treating breast cancer with brain metastases [ID881]
Discontinued [GID-TA10066]
Topotecan for the treatment of recurrent and stage IVB cervical cancer (TA183)
Evidence-based recommendations on topotecan for treating recurrent and stage IVB cervical cancer in adults.
Atezolizumab with paclitaxel for untreated advanced triple-negative breast cancer [ID2705]
Discontinued [GID-TA10570]